NeuroPace (NPCE) Stock Analysis & AI Equity Report

Medical - Devices USD Explore free reports

NeuroPace (NPCE) overview

NeuroPace (NPCE) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 100.0m and operating profit of USD -16.3m; the year-end share price was 15.44 USD and market capitalisation was USD 518m. NeuroPace is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get NeuroPace's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 19.0mFY 2025
Share price15.44 USDFY 2025 year end
RevenueUSD 100.0mFY 2025
Operating profitUSD -16.3mFY 2025
Net earningsUSD -21.5mFY 2025
Market capitalisationUSD 518mFY 2025 year end

About NeuroPace

NeuroPace develops and sells the RNS System, a brain-responsive neuromodulation device for adults with drug-resistant focal epilepsy. Clinicians program the system to monitor brain activity, identify patient-specific abnormal patterns, and deliver electrical pulses at the seizure source. It also records continuous brain data that clinicians can review in person or remotely to inform treatment decisions.

Generate the NeuroPace report

NeuroPace is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for NeuroPace and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on NeuroPace

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.